March 14, 2024
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use...
Spherix Global Insights is a leading provider of life sciences market research, business intelligence and advisory services. The company’s unique service offerings are powered by deep therapeutic knowledge, the Spherix Network specialty physician panel, and commercially relevant analyses to enable strategic decision-making by our valued customers.
A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.
Unparalleled dedication to the life sciences therapeutic areas we cover
The perfect blend of syndicated market research and custom insights
Prepping for the pipeline
Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Methodology: Insights are based on analyses of quantitative data collected from an online survey of specialists, patients, and leading KOLs recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents and select KOLs.
Annual report (n=100-200 physicians)
Qualitative interviews (n=6-8 physicians, n=2-3 KOLs)
Trending market evolution
RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.
Methodology: Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.
US: quarterly report (n=100-200 respondents)
EU5: semiannual report (n=250 respondents)
Canada: semiannual report (n=50 respondents)
Benchmarking new brand performance
Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Methodology: Insights are based on analyses of quantitative data collected from an online survey of physicians “in the trenches” recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents.
Monthly KPI benchmarking (n=75 physicians)
Quarterly report (n=75 physicians)
Quarterly qualitative interviews (n=8 physicians)
Exploring the patient journey
Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.
Report Methodology: Insights are based on patient level data gathered through collaboration with specialty physicians who provide details on clinical and non-clinical patient demographics, along with their rationale for treatment choices.
US: annual patient chart audit (n=1,000 charts, n=200 physicians)
EU5: annual patient chart audit (n=1,250 charts, n=250 physicians)
Gauging impact of disruptive events
Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.
Methodology: Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.
Report cadence and deliverable depend upon current event/topic being evaluated.
March 14, 2024
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use...
March 12, 2024
Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For...
February 23, 2024
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and...
February 22, 2024
Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved...
February 16, 2024
Earlier screening will be needed in the age of biomarkers. EXTON, PA., February 16, 2024 — Millions of people worldwide...
February 08, 2024
Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular...
January 22, 2024
The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class,...
There’s more to know. About the Team